MapLight Therapeutics (MPLT) Research & Development (2024 - 2025)
MapLight Therapeutics' (MPLT) quarterly Research & Development came in at $64.6 million in Q4 2025, up 211.99% year-on-year from $20.7 million in Q4 2024, and up 138.51% quarter-over-quarter from $27.1 million in Q3 2025.
MapLight Therapeutics (MPLT) Research & Development (2024 - 2025) Analysis & Trends
MapLight Therapeutics has disclosed Research & Development across 2 years of filings, most recently posting $64.6 million for Q4 2025.
- Research & Development for Q4 2025 came in at $64.6 million, up 211.99% year-over-year; the trailing twelve-month figure through Dec 2025 was $129.2 million (changed N/A YoY), and the FY2025 annual result was $138.3 million, up 101.9% from the prior year.
- Research & Development came in at $64.6 million for Q4 2025 at MapLight Therapeutics, up from $27.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $64.6 million in Q4 2025 to a low of $16.8 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | MapLight Therapeutics | 248.88 Mn | 248.88 Mn | - | 64.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 64.62 Mn |
| Sep 30, 2025 | 27.09 Mn |
| Dec 31, 2024 | 20.71 Mn |
| Sep 30, 2024 | 16.81 Mn |